See every side of every news story
Published loading...Updated

What Investors Are Missing about Pfizer and Merck - CEO North America

Summary by Chief Executive Officer North America
Here are some key facts when it comes to Pfizer’s drug pipeline, which the company ought to be shouting from the mountaintops at every opportunity and conveying clearly with quantifiable return on invested capital metrics, not only technical scientific data.‌ First, the financial returns on Pfizer’s $43 billion Seagen deal have already exceeded the most optimistic internal estimates, with several oncology drugs poised to become blockbusters. Tha…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Chief Executive Officer North America broke the news in on Wednesday, February 19, 2025.
Sources are mostly out of (0)